

A Randomised Controlled Trial of Antenatal Melatonin Supplementation in
Fetal Growth Restriction for Fetal Neuroprotection.

***Please help us in recruiting 332 women with
severe, early onset IUGR from sites across
Australia and New Zealand over the next 3 years.***

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> GA 23.0 – 31.6 Singleton pregnancy Severe FGR, defined as: <ul style="list-style-type: none"> AC<3rd centile for GA, or; AC<10th centile in combination with at least one abnormal fetoplacental doppler study, being; <ul style="list-style-type: none"> Uterine artery (raised pulsatility index \geq95th centile) Umbilical artery (pulsatility index \geq95th centile or absent/reversed end-diastolic flow) 	<ul style="list-style-type: none"> Known chromosomal, major structural anomaly or non-placental cause for FGR Requires immediate delivery Co-recruitment to another clinical trial where a pharmaceutical product or nutritional supplement is the trial intervention Taking fluvoxamine

An ultrasound will confirm suitability to take part in the trial. If eligible,

- please give brief discussion and a PISC (participant information) to take home**
- email Lisa (Research Midwife/Trial coordinator: lisa.mravicich@auckland.ac.nz)**

One of the research team will make contact to discuss potential enrolment.

Following enrolment, participants will be seen by Renuka Bhat at least fortnightly at Middlemore Hospital for fetal USS and maternal surveillance until birth. General clinical care and timing of delivery will follow local guidelines.

Dr Renuka Bhat, Obstetrics & Gynaecology, CMDHB. Email: Renuka.Bhat@middlemore.co.nz

Dr Chris McKinlay, Neonatologist, Kidz First Neonatal, CMDHB. Email: c.mckinlay@auckland.ac.nz. Phone: 0274 725 099

Lisa Mravicich, Research Midwife/Trial Coordinator, CMDHB. Email: lisa.mravicich@auckland.ac.nz. Phone: 021 430 564